Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Platelet-rich Plasma Therapy in Androgenic Alopecia
NCT03474718Phase 1Not yet recruiting
- Sponsor
- Wake Forest University Health Sciences
- Start
- Dec 2026
- Primary completion
- Jul 2027
- Modality
- Adipose-derived MSCs, Bone Marrow MSCs
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of platelet-rich plasma in androgenetic alopecia (AGA) (2 arms), sponsored by Wake Forest University Health Sciences. Primary endpoint: Severity of Alopecia Tool at 6 months. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
platelet-rich plasma
03
Conditions
androgenetic alopecia (AGA)
Beyond the preview
Go deeper on NCT03474718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03474718.